370 related articles for article (PubMed ID: 17584314)
1. The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease.
Kuo HC; Yang KD; Liang CD; Bong CN; Yu HR; Wang L; Wang CL
Pediatr Allergy Immunol; 2007 Jun; 18(4):354-9. PubMed ID: 17584314
[TBL] [Abstract][Full Text] [Related]
2. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
[TBL] [Abstract][Full Text] [Related]
3. Immunoglobulin failure and retreatment in Kawasaki disease.
Durongpisitkul K; Soongswang J; Laohaprasitiporn D; Nana A; Prachuabmoh C; Kangkagate C
Pediatr Cardiol; 2003; 24(2):145-8. PubMed ID: 12457253
[TBL] [Abstract][Full Text] [Related]
4. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM; Silverman ED; McCrindle BW; Yeung RS
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[TBL] [Abstract][Full Text] [Related]
5. Association of lower eosinophil-related T helper 2 (Th2) cytokines with coronary artery lesions in Kawasaki disease.
Kuo HC; Wang CL; Liang CD; Yu HR; Huang CF; Wang L; Hwang KP; Yang KD
Pediatr Allergy Immunol; 2009 May; 20(3):266-72. PubMed ID: 19438983
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
Khowsathit P; Hong-Hgam C; Khositseth A; Wanitkun S
J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
[TBL] [Abstract][Full Text] [Related]
7. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
Uehara R; Belay ED; Maddox RA; Holman RC; Nakamura Y; Yashiro M; Oki I; Ogino H; Schonberger LB; Yanagawa H
Pediatr Infect Dis J; 2008 Feb; 27(2):155-60. PubMed ID: 18174868
[TBL] [Abstract][Full Text] [Related]
8. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y
Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
[TBL] [Abstract][Full Text] [Related]
9. Management and outcome of intravenous gammaglobulin-resistant Kawasaki disease.
Sittiwangkul R; Pongprot Y; Silvilairat S; Phornphutkul C
Singapore Med J; 2006 Sep; 47(9):780-4. PubMed ID: 16924360
[TBL] [Abstract][Full Text] [Related]
10. Initial intravenous gamma-globulin treatment failure in Iranian children with Kawasaki disease.
Kashef S; Safari M; Amin R
Kaohsiung J Med Sci; 2005 Sep; 21(9):401-4. PubMed ID: 16248123
[TBL] [Abstract][Full Text] [Related]
11. Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease.
Abe J; Ebata R; Jibiki T; Yasukawa K; Saito H; Terai M
J Allergy Clin Immunol; 2008 Nov; 122(5):1008-1013.e8. PubMed ID: 18930517
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Kawasaki disease using locally product intravenous immunoglobulin.
Sangtawesin C; Kirawitaya T; Layangkool T; Nawasiri W; Vimolsarawong N
J Med Assoc Thai; 2003 Aug; 86 Suppl 3():S656-60. PubMed ID: 14700163
[TBL] [Abstract][Full Text] [Related]
13. Serum albumin level predicts initial intravenous immunoglobulin treatment failure in Kawasaki disease.
Kuo HC; Liang CD; Wang CL; Yu HR; Hwang KP; Yang KD
Acta Paediatr; 2010 Oct; 99(10):1578-83. PubMed ID: 20491705
[TBL] [Abstract][Full Text] [Related]
14. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease.
Egami K; Muta H; Ishii M; Suda K; Sugahara Y; Iemura M; Matsuishi T
J Pediatr; 2006 Aug; 149(2):237-40. PubMed ID: 16887442
[TBL] [Abstract][Full Text] [Related]
15. Persistent monocytosis after intravenous immunoglobulin therapy correlated with the development of coronary artery lesions in patients with Kawasaki disease.
Kuo HC; Wang CL; Liang CD; Yu HR; Chen HH; Wang L; Yang KD
J Microbiol Immunol Infect; 2007 Oct; 40(5):395-400. PubMed ID: 17932598
[TBL] [Abstract][Full Text] [Related]
16. Both patient characteristics and IVIG product-specific mechanisms may affect eosinophils in immunoglobulin-treated Kawasaki disease.
Khan S; Doré PC; Sewell WA
Pediatr Allergy Immunol; 2008 Mar; 19(2):186-7. PubMed ID: 18257907
[No Abstract] [Full Text] [Related]
17. Intravenous immunoglobulin therapy induces neutrophil apoptosis in Kawasaki disease.
Tsujimoto H; Takeshita S; Nakatani K; Kawamura Y; Tokutomi T; Sekine I
Clin Immunol; 2002 May; 103(2):161-8. PubMed ID: 12027421
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients.
Sato S; Kawashima H; Kashiwagi Y; Hoshika A
Int J Rheum Dis; 2013 Apr; 16(2):168-72. PubMed ID: 23773640
[TBL] [Abstract][Full Text] [Related]
19. [Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study].
DU ZD; Zhao D; DU JB; Lu S; Yi JM; Hou AC; Zhou ZS; Ding GF;
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3119-21. PubMed ID: 18269869
[TBL] [Abstract][Full Text] [Related]
20. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease.
Kobayashi T; Inoue Y; Takeuchi K; Okada Y; Tamura K; Tomomasa T; Kobayashi T; Morikawa A
Circulation; 2006 Jun; 113(22):2606-12. PubMed ID: 16735679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]